Need to continue or discontinue RAS inhibitors as CKD stage advances? Any alternative?

Hypertens Res. 2023 Aug;46(8):2048-2050. doi: 10.1038/s41440-023-01318-7. Epub 2023 May 30.

Authors

Daisuke Fujimoto¹, Takashige Kuwabara², Masashi Mukoyama¹

Affiliations

¹ Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan.
² Department of Nephrology, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan. ktakasea@kumamoto-u.ac.jp.

PMID: 37253978
DOI: 10.1038/s41440-023-01318-7

No abstract available

Keywords: Advanced CKD; Hyperkalemia; RAS blockade.

Publication types

Editorial
Comment

MeSH terms

Angiotensin-Converting Enzyme Inhibitors / pharmacology
Antihypertensive Agents / pharmacology
Enzyme Inhibitors / pharmacology
Humans
Renal Insufficiency, Chronic* / drug therapy
Renal Insufficiency, Chronic* / physiopathology
Renin-Angiotensin System* / drug effects

Substances

Angiotensin-Converting Enzyme Inhibitors
Antihypertensive Agents
Enzyme Inhibitors